Evidence map›Paper›PMID 35997436›Full record

ArticleInternational journal of neonatal screening2022

Impact of Pancreatitis-Associated Protein on Newborn Screening Outcomes and Detection of CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A Monocentric Prospective Pilot Experience.

Chiara Bianchimani, Daniela Dolce, Claudia Centrone, Silvia Campana, Novella Ravenni, Tommaso Orioli, Erica Camera, Gianfranco Mergni, Cristina Fevola, Paolo Bonomi and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of neonatal screening, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Chiara BianchimaniCystic Fibrosis Regional Reference Center, Department of Paediatric Medicine, Meyer Children's Hospital, 50139 Florence, Italy.
Daniela DolceCystic Fibrosis Regional Reference Center, Department of Paediatric Medicine, Meyer Children's Hospital, 50139 Florence, Italy.
Claudia CentroneDiagnostic Genetics Unit, Careggi University Hospital, 50139 Florence, Italy.
Silvia CampanaCystic Fibrosis Regional Reference Center, Department of Paediatric Medicine, Meyer Children's Hospital, 50139 Florence, Italy.
Novella RavenniCystic Fibrosis Regional Reference Center, Department of Paediatric Medicine, Meyer Children's Hospital, 50139 Florence, Italy.
Tommaso OrioliCystic Fibrosis Regional Reference Center, Department of Paediatric Medicine, Meyer Children's Hospital, 50139 Florence, Italy.
Erica CameraCystic Fibrosis Regional Reference Center, Department of Paediatric Medicine, Meyer Children's Hospital, 50139 Florence, Italy.
Gianfranco MergniCystic Fibrosis Regional Reference Center, Department of Paediatric Medicine, Meyer Children's Hospital, 50139 Florence, Italy.
Cristina FevolaCystic Fibrosis Regional Reference Center, Department of Paediatric Medicine, Meyer Children's Hospital, 50139 Florence, Italy.
Paolo BonomiFreelance Statistician, 20100 Milan, Italy.
Giovanni TaccettiCystic Fibrosis Regional Reference Center, Department of Paediatric Medicine, Meyer Children's Hospital, 50139 Florence, Italy.
Vito TerlizziCystic Fibrosis Regional Reference Center, Department of Paediatric Medicine, Meyer Children's Hospital, 50139 Florence, Italy.ORCID 0000-0003-1106-4424
Meyer Children's Hospital · ITAzienda Ospedaliero-Universitaria Careggi · ITIstituto Nazionale di Statistica · IT

Funding

Tuscany Region K36
6 · The paper itself

Abstract

Pancreatitis-Associated Protein (PAP)-based Cystic Fibrosis (CF) newborn bloodspot screening (NBS) protocols detect less CFTR-Related Metabolic Syndrome (CRMS)/CF Screen Positive, Inconclusive Diagnosis (CFSPID). We prospectively evaluated the impact of PAP as the second step of the CF NBS protocol, before the CFTR genetic analysis, on NBS outcomes and CRMS/CFSPID detection in the Tuscany region, Italy. In parallel to the usual protocol (IRT/DNA, protocol 1), PAP was analyzed in IRT-positive infants (IRT/PAP/DNA, protocol 2) from 1 June 2020 until 31 May 2022. We defined an infant as NBS positive if PAP was >1.8 μg/L for IRT value 99th percentile-100 μg/L or >0.6 μg/L for IRT value >100 μg/L. To increase the positive predictive value (PPV) of protocol 2, we retrospectively lowered the upper IRT range value from 100 to 90 μg/L (modified protocol 2). We identified 8 CF and 13 CRMS/CFSPID with protocol 1, 5 CF and 5 CRMS/CFSPID with protocol 2 and 8 CF and 5 CRMS/CFSPID with modified protocol 2. With the PAP-based protocols, we observed a reduction of sweat tests, healthy carrier detection and a significant increase in PPV to 15.38%. Further data are needed in order to evaluate the outcomes of CRMS/CFSPID after a long follow-up.

Indexed as

outcomesPAPPPVscreeningsweat chloride

Identifiers

PMID35997436
PMCPMC9397086
OpenAlexW4289711912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.